Sidarbenamide

PreclinicalSmall molecule

Sidarbenamide is one of 4 small molecule programs targeting Immune Checkpoint Inhibitors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune Checkpoint InhibitorsNot yet recruiting

Immune Checkpoint InhibitorsPreclinical

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Immune Checkpoint Inhibitors

#DrugCompanyPhaseTrials

Immunotherapy

Bristol-Myers Squibb

Phase 2

2 2

N-803

IImmunityBio, Inc.

Phase 2

1 3

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Phase 2

1 4

Sidarbenamide

JJun Chen, MD

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Immune Checkpoint Inhibitors

NCT06902038

Clinical

Trials by Indication[1]

Immune Checkpoint Inhibitors1 trial

Clinical Research on the Use of Immune Checkpoint Inhibitors Combined With Chidamide for the Functional Cure of AIDS

Not yet recruiting·JJun Chen, MD·N/A·NCT06902038·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sidarbenamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sidarbenamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sidarbenamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jun Chen, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJun Chen, MD

Sidarbenamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Immune Checkpoint Inhibitors1 trial

References

Drug Info

Quick Facts

Related News